21:45 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Critical Outcomes expands Phase I COTI-2 study to HNSCC

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF) expanded an open-label, U.S. Phase I trial evaluating oral COTI-2 in gynecological malignancies to include up to 36 patients with squamous cell carcinoma of the head and neck (SCCHN)...
15:57 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer In vitro and mouse studies suggest a cell-penetrating antibody targeting activated KRAS could help treat KRAS-mutant cancers. In a panel of KRAS-mutant human cancer cell lines, a cell-penetrating IgG1 antibody against KRAS, modified...
13:23 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting KRAS or MCP-1 could help treat malignant pleural effusions in KRAS-mutant cancers. In non-small cell lung cancer (NSCLC) patients, KRAS mutations in metastatic tumors were associated...
17:15 , Apr 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Financial News

Critical Outcome Technologies completes warrant exercise

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2016-06-03   Type: Warrant exercise   Raised: C$1.6 million ($1.3 million)   Shares: 5.8 million   Shares after offering:...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

COTI-2: Phase I started

Critical Outcome began an open-label, U.S. Phase I trial to evaluate oral COTI-2 in up to 46 patients with platinum-resistant, recurrent ovarian, endometrial or cervical cancer. Patients will receive COTI-2 for 5 consecutive days followed...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2015-08-04   Type: Private placement of units   Raised: C$836,560 ($636,622)   Units: 2.8 million   Price: C$0.30 (unit)...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

Critical Outcome Technologies Inc completes private placement of units

Critical Outcome Technologies Inc . (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2015-02-18   Type: Private placement of units   Raised: C$542,990 ($436,510)   Units: 2.1 million   Price: C$0.26...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2014-11-26   Type: Private placement of units   Raised: $702,420   Units: 3.1 million   Price: $0.23 (unit)  ...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2014-11-07   Type: Private placement of units   Raised: $1.2 million   Units: 5.1 million   Price: $0.23 (unit)...